BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35869859)

  • 1. Organ-specific efficacy in advanced non-small cell lung cancer patients treated with first-line single-agent immune checkpoint inhibitors.
    Deng J; Gao M; Gou Q; Xu C; Yan H; Yang M; Li J; Yang X; Wei X; Zhou Q
    Chin Med J (Engl); 2022 Jun; 135(12):1404-1413. PubMed ID: 35869859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases.
    Qiao M; Zhou F; Hou L; Li X; Zhao C; Jiang T; Gao G; Su C; Wu C; Ren S; Zhou C
    Ann Transl Med; 2021 Jan; 9(1):34. PubMed ID: 33553327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Zhu KK; Wei JL; Xu YH; Li J; Rao XR; Xu YZ; Xing BY; Zhang SJ; Chen LC; Dong XR; Zhang S; Li ZY; Liu CW; Meng R; Wu G
    Curr Med Sci; 2023 Apr; 43(2):344-359. PubMed ID: 37002471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 5. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
    Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
    Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
    Front Immunol; 2021; 12():651086. PubMed ID: 34248939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
    Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.
    Hendriks LEL; Bootsma G; Mourlanette J; Henon C; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Duchemann B; Cousin S; le Pechoux C; Botticella A; De Ruysscher D; Dingemans AC; Besse B
    Eur J Cancer; 2019 Jul; 116():182-189. PubMed ID: 31203193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Prognostic Factors of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer.
    Hu YX; Guo LJ; Lin MQ; Lin QY
    Am J Clin Oncol; 2023 Apr; 46(4):161-166. PubMed ID: 36806256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
    Kuo CS; Wang CC; Huang YC; Pavlidis S; Liu CY; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
    Thorac Cancer; 2019 May; 10(5):1158-1166. PubMed ID: 30950239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer-a retrospective cohort study.
    Wang Q; Fang Y; Li C; Leong TL; Provencio M; Oh IJ; Zhang Z; Su C
    Transl Lung Cancer Res; 2023 Feb; 12(2):312-321. PubMed ID: 36895937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
    Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
    BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of medical cannabis concomitantly with immune checkpoint inhibitors in non-small cell lung cancer: A sigh of relief?
    Waissengrin B; Leshem Y; Taya M; Meiri D; Merimsky O; Shamai S; Wolf I; Rubinek T
    Eur J Cancer; 2023 Feb; 180():52-61. PubMed ID: 36535195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis.
    Tian BW; Han CL; Wang HC; Yan LJ; Ding ZN; Liu H; Mao XC; Tian JC; Xue JS; Yang LS; Tan SY; Dong ZR; Yan YC; Wang DX; Li T
    Clin Exp Metastasis; 2023 Aug; 40(4):255-287. PubMed ID: 37308706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
    Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
    JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.
    Kitadai R; Okuma Y; Hakozaki T; Hosomi Y
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):777-785. PubMed ID: 31828427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis.
    Yang K; Li J; Bai C; Sun Z; Zhao L
    Front Oncol; 2020; 10():1098. PubMed ID: 32733805
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.